On January 13, 2010, the sponsor submitted a request for a Special Protocol Assessment (SPA) for the planned Phase 3 study. The proposed primary efficacy endpoint was an improvement in pupillary light reflex. Following feedback from the FDA that this endpoint was not acceptable, the sponsor formally withdrew the SPA request to pursue development of the mobility test as a more clinically meaningful primary endpoint.